DrugPatentWatch Database Preview

Details for Patent: 10,085,958

« Back to Dashboard

Which drugs does patent 10,085,958 protect, and when does it expire?

Patent 10,085,958 protects PROLENSA and is included in one NDA.

This patent has five patent family members in four countries.

Summary for Patent: 10,085,958

Title:	Bromfenac bioavailability
Abstract:	Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY.TM. formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.
Inventor(s):	Padilla; Angel (Aliso Viejo, CA), Baklayan; George (Huntington Beach, CA)
Assignee:	BAUSCH & LOMB PHARMA HOLDINGS CORP. (Rochester, NY)
Application Number:	15/343,457
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,085,958
Patent Claim Types: see list of patent claims	Composition; Formulation;

Drugs Protected by US Patent 10,085,958

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch And Lomb	PROLENSA	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	203168-001	Apr 5, 2013		RX	Yes	Yes			Y

International Family Members for US Patent 10,085,958

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2852995
European Patent Office	2765988
Mexico	2014004347